While the odds of improving ( versus placebo ) were greater for sertraline ( 1.90 [ 0.44-8 .20 ] ; odds ratio [ 95 % CI ] ) than R. rosea ( 1.39 [ 0.38-5 .04 ] ) , more subjects on sertraline reported adverse events ( 63.2 % ) than R. rosea ( 30.0 % ) or placebo ( 16.7 % ) ( p = 0.012 ) .